FDA fast tracks trans-capsaicin treatment for painful foot condition

The FDA has granted fast track designation to trans-capsaicin (CNTX-4975, Centrexion) for the treatment of Morton’s neuroma, a rare, painful nerve disorder in the foot. CNTX-4975 is a highly potent, ultrapure, synthetic form of injectable trans-capsaicin that works by selectively targeting the capsaicin receptor (transient receptor potential vanilloid subtype 1) to rapidly inactivate the local pain fibers transmitting signals to the brain. With a short half-life, trans-capsaicin is cleared from the body within 24 hours.

The FDA has granted fast track designation to trans-capsaicin (CNTX-4975, Centrexion) for the treatment of Morton’s neuroma, a rare, painful nerve disorder in the foot. CNTX-4975 is a highly potent, ultrapure, synthetic form of injectable trans-capsaicin that works by selectively targeting the capsaicin receptor (transient receptor potential vanilloid subtype 1) to rapidly inactivate the local pain fibers transmitting signals to the brain. With a short half-life, trans-capsaicin is cleared from the body within 24 hours.

Link:
FDA fast tracks trans-capsaicin treatment for painful foot condition